MAPT and Alzheimer disease: Moreover, the administration of RGFP-966, a selective HDAC3 inhibitor, improves cognitive function in the AD mouse model and decreases Aβ and tau in neurons from AD patients, further supporting the significant role of HDACi in patients beyond the AD mouse model (173).